Biolegend, 503001, Purified anti-human LT-α (TNF-β) Antibody, 50μg

Lymphotoxin-α (LT-α), also known as tumor necrosis factor-beta (TNF-β), is a potent lymphoid factor that exerts cytotoxic effects on a wide range of tumor cells and certain other target cells. LT-α possesses a signal peptide sequence and is a secreted protein; however, LT-α is also present on the surface of activated T, B and LAK cells as a complex with LT-β. Bioactive LT-α exists as a homotrimer.
50μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: E.coli expressed, recombinant human LT-α.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: ELISA Capture - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 1-4 µg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: ELISA or ELISPOT Capture1,2: The purified 359-238-8 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated 359-81-11 antibody (Cat. No. 503104) as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture. Neutralization1,2: The 359-238-8 antibody can neutralize the bioactivity of human LT-α. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for neutralization of human LT-α bioactivity (Cat. No. 503004).
Application References(PubMed link indicates BioLegend citation): Meager A, et al. 1987. J. Immunol. Methods 104:31. Meager A, et al. 1987. Hybridoma. 6:305.
Product Citations: Ong L, et al. 2016. J Cereb Blood Flow Metab. 10.1177/0271678X16654920. PubMed
RRID: AB_315268 (BioLegend Cat. No. 503002)
Structure: TNF superfamily; trimer; 25 kD (Mammalian)
Bioactivity: Transformed cell cytotoxicity; mediator of inflammatory and immune functions; fibroblast synthesis of GM-CSF, G-CSF, IL-1, collagenase, prostaglandin E2; monocyte terminal differentiation, synthesis of G-CSF; neutrophil chemoattractant, production of reac
Cell Sources: Activated T and B cells, fibroblasts, astrocytes, myeloma, endothelial cells, epithelial cells
Cell Targets: Monocytes, B cells, fibroblasts, neutrophils, osteoclasts, keratinocytes, endothelial cells
Receptors: TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-p80 Type A, p75)
Biology Area: Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Aggarwal B, et al. Eds. 1992. Tumor necrosis factors:structure, function, and mechanism of action. Marcel Dekker Inc. 3. Bonavida B, et al. Eds. 1990. Tumor necrosis factor:structure, mechanisms of action, role in disease and therapy. Karger, Basel. 4. Paul N, et al. 1987. Annu. Rev. Immunol. 6:407.
Regulation: Type II integral membrane protein, forms heterotrimer with type II integral membrane protein LT-β either as LTα1β2 or LTα2β1; processed secreted form is trimeric
Gene ID: 4049
UniProt: View information about LT-alpha on UniProt.org
Clone: 359-238-8
Regulatory Status: RUO
Other Names: Lymphotoxin-α (LT- α), Tumor necrosis factor-β (TNF-β), Coley's toxin, Hemorrhagic factor, Necrosin, Natural killer cytotoxic factor (NKCF), Differentiation inducing factor (DIF), TNFSF-1
Isotype: Mouse IgG1, κ